Published on 28 May 2024 on Benzinga via Yahoo Finance
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Novo Nordisk A/S (NYSE:NVO) has disclosed that it retains approximately 60% of the list price of its diabetes and obesity medications, Ozempic and Wegovy, in the U.S. after accounting for rebates and fees paid to intermediaries.
This revelation comes amid intensifying scrutiny over the cost of these blockbuster drugs.